CoChat

The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Open access
Abushamat, Layla A., Shah, Pir Ahmad, Eckel, Robert H., Harrison, Stephen A., Barb, Diana · 2024 · Clinical Gastroenterology and Hepatology
Cited by 92

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1 in 3-4 adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Insulin resistance plays a central role in MASLD/MASH pathophysiology with higher rates of MASLD (2 in 3) and MASH with fibrosis (1 in 5) in adults with obesity and diabetes. This review summarizes the role of glucagon-like peptide-1 receptor agonists in treating MASLD/MASH. Although not approved by the Food and Drug Administration for the treatment of MASLD, this class of medication is available to treat obesity and type 2 diabetes and has been shown to reverse steatohepatitis, reduce cardiovascular risk, and is safe to use across the spectrum of MASLD with or without fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2024.01.032

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 25

  1. Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466 · DOI · Paper page
  2. Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038/s41591-018-0104-9 · DOI · Paper page
  3. Francque, 2016, Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications, J Hepatol, 65, 425, 10.1016/j.jhep.2016.04.005 · DOI · Paper page
  4. Bril, 2017, Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease, Hepatology, 65, 1132, 10.1002/hep.28985 · DOI · Paper page
  5. Cusi, 2012, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications, Gastroenterology, 142, 711, 10.1053/j.gastro.2012.02.003 · DOI · Paper page
  6. Altarejos, 2011, CREB and the CRTC co-activators: sensors for hormonal and metabolic signals, Nat Rev Mol Cell Biol, 12, 141, 10.1038/nrm3072 · DOI · Paper page
  7. Polyzos, 2010, The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease, Diabetes Obes Metab, 12, 365, 10.1111/j.1463-1326.2009.01176.x · DOI · Paper page
  8. Duval, 2010, Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice, Diabetes, 59, 3181, 10.2337/db10-0224 · DOI · Paper page
  9. Romeo, 2020, Leveraging human genetics to identify potential new treatments for fatty liver disease, Cell Metab, 31, 35, 10.1016/j.cmet.2019.12.002 · DOI · Paper page
  10. Fromenty, 2023, Mitochondrial alterations in fatty liver diseases, J Hepatol, 78, 415, 10.1016/j.jhep.2022.09.020 · DOI · Paper page
  11. Moore, 2022, Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD, Hepatology, 76, 1452, 10.1002/hep.32324 · DOI · Paper page
  12. Sunny, 2017, Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies, Trends Endocrinol Metab, 28, 250, 10.1016/j.tem.2016.11.006 · DOI · Paper page
  13. Lomonaco, 2021, Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening, Diabetes Care, 44, 399, 10.2337/dc20-1997 · DOI · Paper page
  14. Ciardullo, 2021, High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes, Diabetes Care, 44, 519, 10.2337/dc20-1778 · DOI · Paper page
  15. Barb, 2021, Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease, Obesity (Silver Spring), 29, 1950, 10.1002/oby.23263 · DOI · Paper page
  16. Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265 · DOI · Paper page
  17. Kanwal, 2021, Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease, Gastroenterology, 161, 1657, 10.1053/j.gastro.2021.07.049 · DOI · Paper page
  18. Dalsgaard, 2018, Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons, Diabetes Obes Metab, 20, 508, 10.1111/dom.13128 · DOI · Paper page
  19. Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  20. Cefalu, 2018, Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum, Diabetes Care, 41, 14, 10.2337/dci17-0057 · DOI · Paper page
  21. Patel Chavez, 2022, The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD, J Clin Endocrinol Metab, 107, 29, 10.1210/clinem/dgab578 · DOI · Paper page
  22. Yabut, 2023, Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease, Endocr Rev, 44, 14, 10.1210/endrev/bnac018 · DOI · Paper page
  23. Barritt, 2022, Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know, Aliment Pharmacol Ther, 55, 944, 10.1111/apt.16794 · DOI
  24. Li, 2023, Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis, Eur J Gastroenterol Hepatol, 35, 1, 10.1097/MEG.0000000000002471 · DOI
  25. Stoops, 2023, Equity and obesity treatment—expanding Medicaid-covered interventions, N Engl J Med, 388, 2309, 10.1056/NEJMp2303268 · DOI

Cited by

Metadata

Authors
Abushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2024-08
Volume
22
Issue
8
Pages
1565-1574
ISSN
1542-3565 (ISSN-L)
OpenAlex
W4391848433
Cited by
92
References
50
FWCI
24.06
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.